Indian F&O data, and the evidence about what not to trade · educational
GLENMARK · Healthcare
1M / 3M / 1Y
+9.9% / +15.4% / +18.7%
Traded value (60d med)
₹112 cr
Days in F&O ban since 2020
27
Futures OI / 1d change
11.2M / -0.1M
ATM implied vol
25% (vs 24% realized)
📜 Results-day history
Typical move 2.3% · up on the day 33% of 27 events · moved 4%+ in 22% · worst -6.9% / best +8.1%
| Reaction day | Move | Open gap | Next 5d | Announced |
|---|
| 2026-07-28 | -0.5% | +0.2% | +1.8% | after close |
| 2026-05-01 | +0.0% | -0.3% | -1.7% | after close |
| 2026-01-23 | -1.5% | +0.1% | +2.4% | after close |
| 2025-10-20 | -0.5% | -0.2% | -2.2% | after close |
| 2025-07-28 | -0.0% | +0.1% | -3.2% | after close |
| 2025-05-02 | -0.4% | +0.0% | +1.7% | after close |
| 2025-02-14 | -6.2% | +0.4% | -1.7% | during mkt |
| 2024-11-18 | -3.1% | +1.1% | +0.3% | during mkt |
Educational data reference: NOT investment advice. Historical statistics do not predict future results. We are not SEBI-registered advisers. All data from NSE public sources; figures may contain errors. Trading, especially leveraged F&O, can cause significant losses.